Joana Goncalves, the Chief Medical Officer of $ORKA, sold 3,080 shares of the company on 12-19-2025 for an estimated $97,263. We received data on the trade from a recent SEC filing. This was a sale of approximately 67.0% of their shares of this class of stock. Following this trade, they now own 1,518 shares of this class of $ORKA stock.
$ORKA Insider Trading Activity
$ORKA insiders have traded $ORKA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:
- JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 4 sales selling 7,000 shares for an estimated $214,293.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ORKA Hedge Fund Activity
We have seen 56 institutional investors add shares of $ORKA stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIKING GLOBAL INVESTORS LP added 2,666,690 shares (+inf%) to their portfolio in Q3 2025, for an estimated $51,280,448
- FMR LLC added 1,641,150 shares (+29.2%) to their portfolio in Q3 2025, for an estimated $31,559,314
- AVORO CAPITAL ADVISORS LLC added 1,333,340 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,640,128
- PERCEPTIVE ADVISORS LLC added 1,268,021 shares (+inf%) to their portfolio in Q3 2025, for an estimated $24,384,043
- DEEP TRACK CAPITAL, LP added 735,983 shares (+38.4%) to their portfolio in Q3 2025, for an estimated $14,152,953
- POINT72 ASSET MANAGEMENT, L.P. added 707,002 shares (+214.2%) to their portfolio in Q3 2025, for an estimated $13,595,648
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 583,327 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,217,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ORKA Analyst Ratings
Wall Street analysts have issued reports on $ORKA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/13/2025
- Jefferies issued a "Buy" rating on 11/13/2025
- Guggenheim issued a "Buy" rating on 10/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
- Barclays issued a "Overweight" rating on 10/13/2025
To track analyst ratings and price targets for $ORKA, check out Quiver Quantitative's $ORKA forecast page.
$ORKA Price Targets
Multiple analysts have issued price targets for $ORKA recently. We have seen 8 analysts offer price targets for $ORKA in the last 6 months, with a median target of $47.0.
Here are some recent targets:
- Yasmeen Rahimi from Piper Sandler set a target price of $75.0 on 12/18/2025
- Roger Song from Jefferies set a target price of $45.0 on 11/13/2025
- Julian Harrison from BTIG set a target price of $63.0 on 11/13/2025
- Yatin Suneja from Guggenheim set a target price of $60.0 on 10/27/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $40.0 on 10/27/2025
- Etzer Darout from Barclays set a target price of $48.0 on 10/13/2025
- Kaveri Pohlman from Clear Street set a target price of $46.0 on 09/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
